FTH NASDAQ
Faeth Therapeutics, Inc.
1W: -4.0%
1M: +27.4%
3M: +247.0%
YTD: +132.6%
$37.44
-1.56 (-4.00%)
Weekly Expected Move ±12.7%
$28
$33
$37
$42
$47
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$1.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$965.2M
52W Range7.45-42.143
Volume377,112
Avg Volume189,732
Beta-0.28
Dividend—
Analyst Ratings
Company Info
CEOAnand Parikh
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-04
Websitefaeththerapeutics.com
1405 Research Blvd
Rockville, MD 20850
US
Rockville, MD 20850
US
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Latest News
Bank of America Corp DE Raises Holdings in Sensei Biotherapeutics, Inc. $FTH
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Craver Josiah | A-Award | 30,824 | $28.37 | 2026-07-21 |
| Parikh Anand Kiran | A-Award | 398,018 | $28.37 | 2026-07-21 |
| STEPHENSON BRIAN C | P-Purchase | 4,400 | $23.40 | 2026-07-01 |
| STEPHENSON BRIAN C | P-Purchase | 600 | $24.22 | 2026-07-01 |
| STEPHENSON BRIAN C | P-Purchase | 1,910 | $22.95 | 2026-06-30 |